Trials / Completed
CompletedNCT01393106
Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma
A Phase 2 Study to Assess the Efficacy and Safety of GS-1101 (CAL-101) in Patients With Relapsed or Refractory Hodgkin Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy and safety of idelalisib in participants with relapsed of refractory Hodgkin Lymphoma (HL). The primary objective will be to assess the overall response rate. Eligible participants will initiate oral therapy with idelalisib at a starting dose of 150 mg twice daily. Treatment with idelalisib will continue until tumor progression or unacceptable toxicity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Idelalisib | Idelalisib tablets administered orally |
Timeline
- Start date
- 2011-09-01
- Primary completion
- 2014-08-01
- Completion
- 2014-08-01
- First posted
- 2011-07-13
- Last updated
- 2018-11-19
- Results posted
- 2015-12-24
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01393106. Inclusion in this directory is not an endorsement.